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7B2 (IR-7B2) was shown to be released from the PC12 pheochromocytoma cell line (7) . Concentrations of IR-7B2 in plasma were also high in patients with pancreatic islet tumors (8), and such endocrine tumors themselves had a high 7B2 content. Little is known about ffi-7B2 concentrations in plasma of persons of different age groups or with pathological conditions other than neoplastic diseases.
In this study we looked for changes in plasma IR-7B2 with age, gestational weeks, sex, or certain pathological conditions.
MaterIals and Methods

Subjects
We collectedplasma from 96 fasting subjects, three months to 91 years old (mean age 37, SD 30 years; males 37, females 59), and from 23 umbilical cords. We also examined plasma samples from the following additional groups: #{149} Group 1, 101 diabetic patients, with or without diabetic complications. #{149} Group 2,28 patients with hyperthyroidism. #{149} Group 3, seven patients with primary hypothyroidism. #{149} Group 4, 13 patients with hepatic cirrhosis. #{149} Group 5,43 patients with chronic renal failure, regularly undergoing hemodialysis. #{149} Group 6, 35 patients with cerebral vascular accident (cerebral hemorrhage or infarction). #{149} Group 7, 36 pregnant patients (eight to 44) weeks of gestation).
All patients were definitively diagnosed in each case by a combination of clinical and laboratory features. All patients with thyroid disorders had also been assessedby radioimmunoassay of thyroid hormones or thyrotropin and serological examinations. of blood, immediately centrifuged, and the plasma was stored at -20 #{176}C until assay
Radioimmunoassay
The radioimununoassay for 7B2 has been described in full elsewhere (4,5, 7). In brief, a peptide fragment corresponding to residues 23-39 of authentic 7B2 was custom-synthesized (CRB, Cambridge, U.K.) and coxjugated to bovine serum albumin with carbodiimide or glutaraldehyde. The antisera were obtained from lop-eared rabbits immunized with these conjugates, and characterized by assessing their binding of labeled synthetic 7B2 fragment. lodination of 7B2 fragment was performed by the Chlorainine T method.
Plasma samples (100 or 200 mL) were assayed in duplicate in a total volume of 0.8 mL. The standard diluent in this radioimmunoassay was 60 mmol/L phosphate buffer, pH 7.4, containing 10 mmol of EDTA, 7.5 mmol of sodium azide, and 150 imol of bovine serum albumin per liter. We used commercial kits to measure the concentrations of pancreatic glucagon (9) and insulin (10) in the plasma samples.
Gel-Permeation Chromatography
We used gel-permeation chromatography on a 1.4 cm x 90 cm column of Sephadex G-100 (Pharmacia Fine Chemicals AB, Uppsala, Sweden) to assay selected plasma samples. The peptide was eluted from the column at 4#{176}C with the standard RIA diluent containing sodium chloride, 200 mmolJL, at a flow rate of 3.2 mLfh. The column was calibrated with Dextran Blue (Mr 2000000), horse heart cytochrome c (Mr 12 384), and a trace amount of Na'25!. The eluted fractions and applied samples were analyzed for IR-7B2.
Blood glucose was determined by a glucose oxidase meth-
Inc., Tokyo, Japan). Blood urea nitrogen, serum creatinine, and cholinesterase activity were also determined with an automated analyzer (Model 736-60; Hitachi Inc., Tokyo, Japan). Glycated hemoglobin was determined by ion-exchange chromatography (HLC-723 Glib;
Toyo Soda Inc., Tokyo, Japan). Figure 2 illustrates a small but significant increase in plasma IR-7B2 30 mm after glucose ingestion in controls and patients with diabetes mellitus. Hyperthyroid patients showed no significant changes in IR-7B2 plasma but did give an exaggerated insulin response (Figure 2c) .
Results
Concentrations
IR-7B2 response after oral glucose load.
Gel-permeation chromatography. We obtained gel-chromatographic profiles of selected samples of cord blood and of plasma from patients with chronic renal failure. All samples showed two iminunoreactive peaks, the earlier peak emerging at a Kay of 0.30 and the second at a Kay of 0.63 (Figure 3) . The earlier peak contained 90% of the total immunoreactivity in each chromatographic run; it co-eluted with the principal peak of IR-7B2 from porcine pituitary gland.
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Fraction Number Fraction Number  Fig. 3 . Sephadex G-100 gel-permeation profiles of IR-7B2 in plasma from a cord-blood sample (Wi) and froma patient with chronic renal failure (right)
The columnwas calibratedwith DextranBlue (Dex)and horseheartcytochrome plasma (14) . These findings may be related to our finding of high concentrations of circulating IR-7B2 in the elderly. In patients with diabetes mellitus or hyperthyroidism, significant changes in plasma IR-7B2 were not observed, and the response to oral glucose was similar for controls and diabetics. Immunohistochemically, 7B2 has been demonstrated in the pancreatic beta cell (8), but the 7B2 response to glucose proved to be different from that of insulin; thus, the majority of plasma 7B2 may be released from tissues other than the pancreas. 7B2 iiumunoreactivity is indeed found not only in pituitary and pancreas but also in neural tissues.
The exact source of plasma IR-7B2 needs further investigation. The high concentrations of circulating IR-7B2 in patients with chronic renal failure may indicate its catabolism or clearance by the kidney. In contrast, the concentrations in patients with liver cirrhosis were not significantly different from the values in controls. In addition to its high concentrations in patients with chronic renal failure, plasma IR-7B2 surprisingly increased after hemodialysis. 7B2 immunoreactivity is present in the neurointermediate lobe of the pituitary and specific hypothalamic nuclei in rats (15) (16) (17) ,but is diminished in the Brattleboro rat (16); therefore, an increment in plasma IR-7B2 might be linked to the volume change accompanying hemodialysis. We have also observed a reduction in weight after hemodialysis and a significant decrease in plasma alpha-atrial natriuretic peptide in these samples (unpublished data).
Plasma samples from pregnant patients in the third trimester also showed high concentrations of IR-7B2. This finding could be related to the high IR-7B2 concentrations in cord blood. The concentrations of 7B2 in plasma were otherwise constant in healthy adults and in the pathological conditions studied, except for chronic renal failure. Plasma 7B2 may therefore serve as a marker of endocrine tumors, but attention must be paid when evaluating concentrations of 7B2 in plasma from subjects with renal failure, or from subjects <10 or >70 years of age.
